Have a feature idea you'd love to see implemented?
Let us know!
RAPT RAPT Therapeutics Inc
Price (delayed)
$1.05
Market cap
$36.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.78
Enterprise value
$3.93M
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
Highlights
The debt is down by 31% year-on-year and by 11% since the previous quarter
RAPT Therapeutics's quick ratio has increased by 22% QoQ and by 12% YoY
RAPT's equity is down by 45% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of RAPT
Market
Valuations
Earnings
Shares outstanding
34.96M
Market cap
$36.71M
Enterprise value
$3.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$107.49M
EBITDA
-$103.92M
Free cash flow
-$100.8M
Per share
Balance sheet
Liquidity
EPS
-$2.78
Free cash flow per share
-$2.59
Book value per share
$2.74
Revenue per share
$0
TBVPS
$2.79
Total assets
$108.47M
Total liabilities
$12.96M
Debt
$5.12M
Equity
$95.51M
Working capital
$92.24M
Debt to equity
0.05
Current ratio
9.9
Quick ratio
9.45
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-76.1%
Return on equity
-89.1%
Return on invested capital
-121.8%
Return on capital employed
-109.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RAPT stock price
How has the RAPT Therapeutics stock price performed over time
Intraday
-1.87%
1 week
-17.97%
1 month
-36.17%
1 year
-92.29%
YTD
-95.77%
QTD
-47.76%
Financial performance
How have RAPT Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$114.85M
Net income
-$107.49M
Gross margin
N/A
Net margin
N/A
The net income has grown by 11% from the previous quarter
RAPT's operating income is up by 11% QoQ and by 2.9% YoY
Growth
What is RAPT Therapeutics's growth rate over time
Valuation
What is RAPT Therapeutics stock price valuation
P/E
N/A
P/B
0.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
RAPT's EPS is up by 11% since the previous quarter and by 3.8% year-on-year
The P/B is 91% lower than the 5-year quarterly average of 4.1 and 85% lower than the last 4 quarters average of 2.5
RAPT's equity is down by 45% year-on-year and by 13% since the previous quarter
Efficiency
How efficient is RAPT Therapeutics business performance
The ROIC has plunged by 97% YoY and by 6% from the previous quarter
The return on equity has dropped by 71% year-on-year and by 3.6% since the previous quarter
RAPT's ROA has shrunk by 63% YoY and by 3.7% QoQ
Dividends
What is RAPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RAPT.
Financial health
How did RAPT Therapeutics financials performed over time
RAPT Therapeutics's total liabilities has plunged by 52% YoY and by 28% from the previous quarter
The total assets has contracted by 46% YoY and by 15% from the previous quarter
The debt is 95% smaller than the equity
RAPT's equity is down by 45% year-on-year and by 13% since the previous quarter
The debt is down by 31% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.